Genzyme asks FDA to expand clofarabine's use to adults

11/24/2008 | American City Business Journals

Genzyme submitted an application seeking FDA approval to market clofarabine to treat adults with acute myeloid leukemia. The biotech firm already sells the drug under the brand Clolar for relapsed and treatment-resistant patients between ages 1 and 21 who suffer from acute lymphoblastic leukemia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA